The PASSPORT clinical trial investigating a new investigational treatment for PSP
INFORMATION FOR HEALTHCARE PROFESSIONALS ABOUT THE PASSPORT CLINICAL TRIAL FOR PROGRESSIVE SUPRANUCLEAR PALSY (PSP)
This is a phase 2b trial designed to evaluate the efficacy and safety of an investigational study medication in PSP patients. The main trial lasts just over a year. It is divided into a 6-week screening period and a 52-week double-blind dosing period, when either the investigational study medication or placebo is given, with clinic visits approximately every 4 weeks. Once this portion of the trial concludes, there will also be an opportunity to participate in an open-label dosing period.
PSP is a rare, tau-based neurodegenerative disorder. The investigational study drug is an antibody which sticks to toxic tau and helps remove it from the space between the cells of the brain. It may prevent the spreading of toxic tau to normal cells.